Angelo Avogaro

38.0k total citations · 2 hit papers
523 papers, 20.1k citations indexed

About

Angelo Avogaro is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Angelo Avogaro has authored 523 papers receiving a total of 20.1k indexed citations (citations by other indexed papers that have themselves been cited), including 277 papers in Endocrinology, Diabetes and Metabolism, 166 papers in Molecular Biology and 98 papers in Surgery. Recurrent topics in Angelo Avogaro's work include Diabetes Treatment and Management (145 papers), Diabetes Management and Research (118 papers) and Metabolism, Diabetes, and Cancer (82 papers). Angelo Avogaro is often cited by papers focused on Diabetes Treatment and Management (145 papers), Diabetes Management and Research (118 papers) and Metabolism, Diabetes, and Cancer (82 papers). Angelo Avogaro collaborates with scholars based in Italy, United States and France. Angelo Avogaro's co-authors include Gian Paolo Fadini, Saula Vigili de Kreutzenberg, Antonio Tiengo, Carlo Agostini, Mattia Albiero, Benedetta Maria Bonora, Claudio Cobelli, Lisa Menegazzo, Mauro Luciano Baesso and Saula de Kreutzenberg and has published in prestigious journals such as Circulation, Journal of Clinical Investigation and Journal of the American College of Cardiology.

In The Last Decade

Angelo Avogaro

505 papers receiving 19.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus

2005 592 citations Gian Paolo Fadini, Antonio Tiengo et al. profile →
Prevalence and impact of diabetes among people infected with SARS-CoV-2

2020 358 citations Gian Paolo Fadini, Mario Luca Morieri et al. profile →

Peers

Countries citing papers authored by Angelo Avogaro

Since Specialization

Citations

This map shows the geographic impact of Angelo Avogaro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Avogaro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Avogaro more than expected).

Fields of papers citing papers by Angelo Avogaro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angelo Avogaro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Avogaro. The network helps show where Angelo Avogaro may publish in the future.

Co-authorship network of co-authors of Angelo Avogaro

This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Avogaro. A scholar is included among the top collaborators of Angelo Avogaro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Avogaro. Angelo Avogaro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐Term Effectiveness of Once‐Weekly Semaglutide in Patients With Type 2 Diabetes Previously Treated With Insulin. A Multicentre Real‐World Study 2025 ·Diabetes/Metabolism Research and Reviews ·Benedetta Maria Bonora, Andrea Giaccari, Agostino Consoli, Fabio Broglio, Angelo Avogaro, Gian Paolo Fadini, (unknown)	0
2	Incretins and the cardiovascular system: bridging digestion with metabolism 2025 ·The Lancet Diabetes & Endocrinology ·Angelo Avogaro, Gian Paolo Fadini	1
3	GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes 2024 ·Acta Diabetologica ·Stefano Ciardullo, Mario Luca Morieri, (unknown), Teresa Vanessa Fiorentino, Teresa Mezza, Domenico Tricò, Agostino Consoli, Stefano Del Prato, Francesco Giorgino, Salvatore Piro, Anna Solini, Angelo Avogaro	9
4	Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications 2024 ·Reviews in Endocrine and Metabolic Disorders ·(unknown), Evelina Maines, Federico Boscari, Livia Lenzini, Gian Paolo Fadini, Alberto Burlina, Angelo Avogaro, Nicola Vitturi	1
5	Renal Replacement Therapy in Methylmalonic Aciduria-Related Metabolic Failure: Case Report and Literature Review 2024 ·Journal of Clinical Medicine ·(unknown), Nicola Vitturi, Gianni Carraro, Livia Lenzini, (unknown), Ilaria Fasan, (unknown), Alberto Burlina, Angelo Avogaro, Lorenzo A. Calò	0
6	Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care 2024 ·Diabetologia ·Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, Enzo Bonora, Agostino Consoli, Bruno Fattor, Mauro Rigato, Federica Turchi, Stefano Del Prato, Angelo Avogaro, Anna Solini, (unknown)	7
7	Circulating haematopoietic stem cells and long‐term outcomes of COVID‐19 2023 ·European Journal of Clinical Investigation ·Benedetta Maria Bonora, (unknown), Paola Fogar, (unknown), Roberta Cappellari, (unknown), Anna Ferrari, Anna Maria Cattelan, Angelo Avogaro, Daniela Basso, Gian Paolo Fadini	1
8	Increased Soluble Interleukin 6 Receptors in Fabry Disease 2023 ·Journal of Clinical Medicine ·Livia Lenzini, Elisabetta Iori, Monica Vettore, (unknown), Claudia Maria Radu, Andrea Padoan, Gianni Carraro, Paolo Simioni, Lorenzo A. Calò, Angelo Avogaro, Gian Paolo Rossi, Nicola Vitturi	0
9	Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes 2022 ·Computer Methods and Programs in Biomedicine ·Enrico Longato, Mario Luca Morieri, Giovanni Sparacino, Barbara Di Camillo, Anna Maria Cattelan, (unknown), Marco Trevenzoli, Andrea Vianello, Gabriella Guarnieri, (unknown), Angelo Avogaro, Paola Fioretto, Roberto Vettor, Gian Paolo Fadini	5
10	Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives 2021 ·Reviews in Endocrine and Metabolic Disorders ·Federico Boscari, Angelo Avogaro	31
11	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society 2021 ·Nutrition Metabolism and Cardiovascular Diseases ·Raffaele Napoli, Angelo Avogaro, Gloria Formoso, Salvatore Piro, Francesco Purrello, Giovanni Targher, Agostino Consoli	14
12	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation 2021 ·ClinicoEconomics and Outcomes Research ·Lucrezia Ferrario, (unknown), Angelo Avogaro, Chiara Bellia, Federico Bertuzzi, Graziella Bonetti, Antonio Ceriello, Marcello Ciaccio, (unknown), Elena Dozio, Luca Falqui, Angela Girelli, Antonio Nicolucci, Gianluca Perseghin, Mario Plebani, Umberto Valentini, Martina Zaninotto, Silvana Castaldi, Emanuela Foglia	4
13	Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes 2020 ·European Journal of Preventive Cardiology ·Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini	13
14	Comparative effectiveness of dapagliflozin vs DPP‐4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world 2020 ·Diabetes/Metabolism Research and Reviews ·Mario Luca Morieri, Agostino Consoli, Giorgio Sesti, Francesco Purrello, Angelo Avogaro, Gian Paolo Fadini, (unknown)	14
15	Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors 2019 ·BMJ Open Diabetes Research & Care ·Gian Paolo Fadini, Mayur Sarangdhar, Fabrizio De Ponti, Angelo Avogaro, Emanuel Raschi	31
16	Il trattamento del diabete mellito di tipo 2: la sicurezza cardiovascolare dei farmaci incretinici confermata dagli studi ELIXA e TECOS 2016 ·Giornale italiano di cardiologia ·Angelo Avogaro	1
17	La malattia cardiovascolare nel paziente diabetico: fattori di rischio, storia clinica e prevenzione 2016 ·Giornale italiano di cardiologia ·Angelo Avogaro	2
18	Ipoglicemia e rischio cardiovascolare 2014 ·Giornale italiano di cardiologia ·Angelo Avogaro	2
19	Glucose Tolerance during Moderate Alcohol Intake: Insights on Insulin Action from Glucose/Lactate Dynamics 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Angelo Avogaro	11
20	Glucose Tolerance during Moderate Alcohol Intake: Insights on Insulin Action from Glucose/Lactate Dynamics 2002 ·The Journal of Clinical Endocrinology & Metabolism ·Angelo Avogaro, Richard M. Watanabe, Lucia Gottardo, Saula de Kreutzenberg, Antonio Tiengo, Giovanni Pacini	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact